Am Fam Physician. 2022;106(1):100-101
Author disclosure: No relevant financial relationships.
• HFNO use reduces all-cause mortality compared with NIV in hypoxemic respiratory failure. |
• When respiratory failure occurs after extubation, positive airway pressure or face mask oxygen may be equal to or more effective than HFNO at reducing symptoms. |
• Aerosol generation is a significant risk of using HFNO. |
From the AFP Editors |
High-flow nasal oxygen (HFNO) is commonly used in acute respiratory failure. Acute hypoxemic respiratory failure is defined as an oxygen saturation below 88% or a baseline partial pressure of arterial oxygen to fractional inspired oxygen concentration ratio of less than 200 mm Hg. In HFNO, warm and humidified oxygen is supplied by nasal cannula at a flow rate up to 60 L per minute. Other options for treating respiratory failure include noninvasive ventilation (NIV) with continuous or bilevel positive airway pressure ventilation and conventional oxygen therapy with low-flow nasal oxygen or oxygen delivered by face mask. The American College of Physicians published guidelines for use of HFNO in adults based on a systematic review focusing on all-cause mortality, hospital length of stay, hospital-acquired pneumonia, intubation/reintubation, intensive care unit admissions, and patient comfort.
Subscribe
From $165- Immediate, unlimited access to all AFP content
- More than 130 CME credits/year
- AAFP app access
- Print delivery available
Issue Access
$59.95- Immediate, unlimited access to this issue's content
- CME credits
- AAFP app access
- Print delivery available